X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (16) 16
humans (14) 14
respiratory system (13) 13
male (10) 10
pulmonary disease, chronic obstructive - drug therapy (9) 9
female (8) 8
middle aged (8) 8
administration, inhalation (7) 7
chronic obstructive pulmonary disease (7) 7
corticosteroids (7) 7
lung diseases, obstructive (7) 7
obstructive pulmonary-disease (7) 7
aged (6) 6
copd (6) 6
double-blind method (6) 6
exacerbations (6) 6
pneumonia (6) 6
treatment outcome (6) 6
adult (5) 5
double-blind (5) 5
salmeterol (5) 5
vilanterol (5) 5
biomarkers (4) 4
bronchodilator agents - administration & dosage (4) 4
disease progression (4) 4
dose-response relationship, drug (4) 4
pharmacology & pharmacy (4) 4
propionate (4) 4
pulmonary disease, chronic obstructive - blood (4) 4
pulmonary disease, chronic obstructive - physiopathology (4) 4
pulmonary/respiratory (4) 4
research (4) 4
risk (4) 4
adrenal cortex hormones - administration & dosage (3) 3
androstadienes - administration & dosage (3) 3
benzyl alcohols - administration & dosage (3) 3
benzyl alcohols - adverse effects (3) 3
chlorobenzenes - administration & dosage (3) 3
chlorobenzenes - adverse effects (3) 3
clinical trials (3) 3
confidence intervals (3) 3
critical care medicine (3) 3
diseases of the respiratory system (3) 3
fluticasone furoate (3) 3
forced expiratory volume (3) 3
inhaled fluticasone furoate (3) 3
lung-function (3) 3
medical research (3) 3
medicine, experimental (3) 3
mu-g (3) 3
prevention (3) 3
pulmonary disease, chronic obstructive - complications (3) 3
risk factors (3) 3
studies (3) 3
time factors (3) 3
1506 (2) 2
adrenal cortex hormones - therapeutic use (2) 2
adrenergic beta-2 receptor agonists - administration & dosage (2) 2
adrenergic beta-2 receptor agonists - adverse effects (2) 2
aged, 80 and over (2) 2
androstadienes - adverse effects (2) 2
antidiabetic agent (2) 2
asthma (2) 2
bacterial pneumonia (2) 2
blood (2) 2
bronchodilator agents - adverse effects (2) 2
care and treatment (2) 2
chromans - pharmacokinetics (2) 2
community-acquired pneumonia (2) 2
copd exacerbations (2) 2
corticoids (2) 2
cs-045 (2) 2
dosage and administration (2) 2
drug administration schedule (2) 2
drug therapy (2) 2
drug therapy, combination (2) 2
eosinophils (2) 2
eosinophils - cytology (2) 2
fluticasone-salmeterol drug combination - administration & dosage (2) 2
glucocorticoids - administration & dosage (2) 2
glycemic control (2) 2
hypoglycemic agents - pharmacokinetics (2) 2
ics (2) 2
increased mortality (2) 2
international journal of chronic obstructive pulmonary disease (2) 2
leukocyte count (2) 2
leukocytes (2) 2
lung diseases (2) 2
metaanalysis (2) 2
metabolism (2) 2
mice (2) 2
neutrophils (2) 2
non-insulin-dependent diabetes mellitus (2) 2
obstructive lung disease (2) 2
original research (2) 2
patients (2) 2
pharmaceutical industry (2) 2
physiology (2) 2
pneumonia - epidemiology (2) 2
pneumonia - etiology (2) 2
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Earth Sciences (Noranda) - Circulation Desk (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Physics - Circulation Desk (1) 1
Physics - Stacks (1) 1
Robarts - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Respiratory Journal, ISSN 0903-1936, 01/2016, Volume 47, Issue 1, pp. 353 - 354
Suissa [1] provides the event-based number needed to treat (NNT) for a reduction in exacerbations with fluticasone/salmeterol compared with placebo for the... 
Humans | Pulmonary Disease, Chronic Obstructive | Disease Progression
Journal Article
Thorax, ISSN 0040-6376, 02/2016, Volume 71, Issue 2, pp. 118 - 125
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2013, Volume 1, Issue 3, pp. 210 - 223
Journal Article
Journal Article
Journal Article
Chest, ISSN 0012-3692, 10/2018, Volume 154, Issue 4, pp. 748A - 749A
Journal Article
EUROPEAN RESPIRATORY JOURNAL, ISSN 0903-1936, 09/2019, Volume 54, Issue 3
Journal Article
Therapeutic Innovation & Regulatory Science, ISSN 2168-4790, 7/2016, Volume 50, Issue 4, pp. 455 - 463
Product labels are intended to provide health care professionals with clear and concise prescribing information that will enhance the safe and effective use of... 
Adverse drug reactions | Harms | Adverse events | Product label | Product safety | adverse drug reactions | product label | MEDICAL INFORMATICS | REGRESSION-MODELS | CLINICAL-TRIALS | harms | MISSING DATA | PREVENTION | PHARMACOLOGY & PHARMACY | product safety | adverse events | Studies | Confidence intervals | Clinical trials | Authorship | Pharmaceutical industry
Journal Article
Respiratory Research, ISSN 1465-9921, 02/2015, Volume 16, Issue 1, pp. 25 - 25
Background: Fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg is a once-daily inhaled corticosteroid (ICS)/long-acting beta(2) agonist (LABA) treatment... 
Vilanterol | Mixed treatment comparison | ICS/LABA | Network meta-analysis | Fluticasone furoate | COPD | MODERATE | METAANALYSIS | SAFETY | MU-G | LUNG-FUNCTION | SALMETEROL | PROPIONATE | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | DOUBLE-BLIND | PROPIONATE/SALMETEROL | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Benzyl Alcohols - administration & dosage | Benzyl Alcohols - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Recovery of Function | Chlorobenzenes - administration & dosage | Forced Expiratory Volume | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Female | Bronchodilator Agents - adverse effects | Pulmonary Disease, Chronic Obstructive - diagnosis | Drug Administration Schedule | Risk Factors | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Disease Progression | Fluticasone-Salmeterol Drug Combination - administration & dosage | Randomized Controlled Trials as Topic | Adrenal Cortex Hormones - adverse effects | Androstadienes - administration & dosage | Chlorobenzenes - adverse effects | Lung - drug effects | Bayes Theorem | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Androstadienes - adverse effects | Budesonide, Formoterol Fumarate Drug Combination - administration & dosage | Adrenal Cortex Hormones - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Research | Drug therapy | Steroids | LABA | ICS
Journal Article
Thorax, ISSN 0040-6376, 02/2016, Volume 71, Issue 2, p. 118
  Objective We performed a review of studies of fluticasone propionate (FP)/salmeterol (SAL) (combination inhaled corticosteroid (ICS)/long-acting β2-agonist... 
Studies | Biomarkers | Population | Antibiotics | Decision making | Quality of life
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 142, Issue 1, pp. 119 - 127
Background Vilanterol (GW642444M) (VI) is a novel, inhaled, long-acting β2 agonist with inherent 24-h activity under development as a once-daily combination... 
Pulmonary/Respiratory
Journal Article
International journal of chronic obstructive pulmonary disease, ISSN 1176-9106, 2018, Volume 13, pp. 3669 - 3676
Background: Growing evidence suggests that blood eosinophil count is associated with patient responsiveness to inhaled corticosteroids (ICS). We performed post... 
ICS | FEV1 | Lung function | COPD | VILANTEROL | RANDOMIZED CONTROLLED-TRIALS | OBSTRUCTIVE PULMONARY-DISEASE | lung function | RESPIRATORY SYSTEM | DOUBLE-BLIND | EXTRAFINE BECLOMETHASONE/FORMOTEROL | FLUTICASONE FUROATE | Medicine, Experimental | Medical research | Tiotropium | Lung diseases, Obstructive | Corticosteroids | chronic obstructive pulmonary disease
Journal Article
BMJ Open Respiratory Research, ISSN 2052-4439, 2016, Volume 3, Issue 1, p. e000151
Sputum and blood eosinophil counts have attracted attention as potential biomarkers in chronic obstructive pulmonary disease (COPD). One question regarding the... 
Journal Article
International Journal of COPD, ISSN 1176-9106, 01/2018, Volume 13, pp. 189 - 201
Background: Patients with COPD are at risk for life-threatening pneumonia. Although anatomical abnormalities in the thorax may predispose to pneumonia, those... 
Pneumonia | Predictors of risk | Chest X-rays | COPD | chest X-rays | COMMUNITY-ACQUIRED PNEUMONIA | OBSTRUCTIVE PULMONARY-DISEASE | pneumonia | PNEUMOCOCCAL DISEASE | RESPIRATORY SYSTEM | predictors of risk | RISK | Medical research | Care and treatment | Lung diseases, Obstructive | Bacterial pneumonia | Analysis | Clinical trials | Medicine, Experimental
Journal Article
The Lancet Respiratory Medicine, ISSN 2213-2600, 09/2019, Volume 7, Issue 9, pp. 745 - 756
Previous studies have highlighted a relationship between reduction in rate of exacerbations with therapies containing inhaled corticosteroids (ICS) and... 
INHALED FLUTICASONE FUROATE | VILANTEROL | CIGARETTE-SMOKING | EFFICACY | RESPIRATORY SYSTEM | DOUBLE-BLIND | EXACERBATIONS | ASTHMA | CORTICOSTEROIDS | ECONOMIC BURDEN | COPD | CRITICAL CARE MEDICINE
Journal Article